Selective PI3K Inhibitors via Indazole Core Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3-kinase inhibitors lack specificity, affecting all Class I PI3Ks equally and not targeting individual members effectively, which limits their therapeutic potential in treating various disorders mediated by PI3-kinase activity.
Innovation Solution
Development of novel compounds that selectively inhibit specific PI3-kinases, such as PI3Kδ, to treat disorders like asthma, COPD, autoimmune diseases, and cancers by modulating T-cell mediated inflammatory responses and vascular permeability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective PI3-kinase inhibitors are used, then broad PI3K inhibition is achieved, but specificity for individual PI3K members is lost
Solution Approach 1:
The patent segments the broad PI3K inhibition into selective inhibition of specific PI3K isoforms (PI3Kδ, PI3Kα, PI3Kβ, PI3Kγ) by designing compounds with specific structural features that target particular isoforms. The indazole core structure with specific substituents (R1-R6 groups) enables differentiation between PI3K family members, allowing selective targeting while maintaining the overall inhibitory mechanism.
Solution Approach 2:
The patent applies local quality by introducing specific substituent patterns at different positions of the indazole core structure. Different R groups (e.g., R1 as halogen, R2 as alkyl, R3 as aryl, R4-R6 as various functional groups) create local chemical environments that confer selectivity for specific PI3K isoforms, allowing the molecule to maintain broad inhibitory capability while achieving isoform-specific targeting.
2Reliability
If selective PI3-kinase inhibitors are developed, then therapeutic potential for specific disorders is improved, but complexity of compound design increases
Solution Approach 1:
The patent employs a universal indazole core structure that serves multiple functions: it provides the basic scaffolding for PI3K inhibition, enables isoform selectivity through substituent variation, and maintains pharmacological activity across different PI3K targets. This multi-functional core simplifies the design process by providing a reliable platform that can be systematically modified for different therapeutic indications.
Solution Approach 2:
The patent systematically varies chemical parameters (substituent types, positions, and combinations) of the indazole core to optimize selectivity and activity. By changing parameters such as the nature of R groups (halogen, alkyl, aryl, functional groups), their positions, and their combinations, the patent achieves reliable therapeutic potential while following a systematic design approach rather than random complexity.
Data Source
AI summary
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.